Compare Two Types News Today

After achieving primary endpoint by demonstrating non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients...

After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients achieve significantly more time in target blood glucose range (Time in Range) vs once-daily basal insulin glargine U100 in ONWARDS 11In the ONWARDS 1 and 3 trials, more people achieved blood glucose targets without clinically significant or severe hypoglycaemia with once-weekly basal insulin icodec vs once-daily basal insulin

After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients achieve significantly more time in target blood glucose range (Time in Range) vs once-daily basal insulin glargine U100 in ONWARDS 11In the ONWARDS 1 and 3 trials, more people achieved blood glucose targets without clinically significant or severe hypoglycaemia with once-weekly basal insulin icodec vs once-daily basal insulin

After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec...

Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trialBagsværd, Denmark, Thursday 22 September 2022 – Novo Nordisk today presented new data from the phase 3a ONWARDS 2 trial, demonstrating that 37% of adults with...